Virtu KCG Holdings LLC boosted its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA) by 36.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,130 shares of the biopharmaceutical company’s stock after purchasing an additional 13,512 shares during the period. Virtu KCG Holdings LLC owned about 0.15% of Cara Therapeutics worth $772,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in CARA. FMR LLC grew its position in Cara Therapeutics by 931.6% in the first quarter. FMR LLC now owns 938,776 shares of the biopharmaceutical company’s stock valued at $17,264,000 after purchasing an additional 847,777 shares in the last quarter. UBS Asset Management Americas Inc. bought a new position in Cara Therapeutics in the first quarter valued at $5,251,000. Morgan Stanley grew its position in Cara Therapeutics by 360.3% in the first quarter. Morgan Stanley now owns 332,606 shares of the biopharmaceutical company’s stock valued at $6,117,000 after purchasing an additional 260,344 shares in the last quarter. Chescapmanager LLC grew its position in Cara Therapeutics by 30.4% in the first quarter. Chescapmanager LLC now owns 893,390 shares of the biopharmaceutical company’s stock valued at $16,429,000 after purchasing an additional 208,223 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Cara Therapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 1,107,874 shares of the biopharmaceutical company’s stock valued at $17,050,000 after purchasing an additional 164,247 shares in the last quarter. 61.13% of the stock is owned by institutional investors and hedge funds.

Shares of Cara Therapeutics, Inc. (NASDAQ CARA) opened at 13.80 on Thursday. The stock’s 50 day moving average is $13.45 and its 200-day moving average is $15.86. Cara Therapeutics, Inc. has a 1-year low of $5.85 and a 1-year high of $28.50. The firm’s market cap is $449.62 million.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.32. During the same quarter in the prior year, the business posted ($0.48) earnings per share. The business’s quarterly revenue was down 100.0% compared to the same quarter last year. Analysts expect that Cara Therapeutics, Inc. will post ($1.78) earnings per share for the current year.

In related news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of the business’s stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $15.00, for a total value of $45,000.00. Following the transaction, the vice president now directly owns 120,000 shares of the company’s stock, valued at approximately $1,800,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Derek T. Chalmers sold 25,000 shares of the business’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $15.05, for a total transaction of $376,250.00. Following the completion of the transaction, the chief executive officer now directly owns 1,107,292 shares in the company, valued at $16,664,744.60. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/virtu-kcg-holdings-llc-has-772000-position-in-cara-therapeutics-inc-cara/1609878.html.

A number of research analysts recently weighed in on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price target (down previously from $24.00) on shares of Cara Therapeutics in a research note on Friday, June 23rd. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Cara Therapeutics in a research note on Thursday, June 22nd. Vetr cut shares of Cara Therapeutics from a “strong-buy” rating to a “buy” rating and set a $21.73 price target for the company. in a research note on Wednesday, June 21st. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Cara Therapeutics in a research note on Wednesday, June 21st. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $27.00 price target on shares of Cara Therapeutics in a research note on Saturday, July 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Cara Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.43.

Cara Therapeutics Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.